Document is current
Any future updates will be listed below
-
Authors
Craig, Stephanie G.
Humphries, Matthew P.
Alderdice, Matthew
Bingham, Victoria
Richman, Susan D.
Loughrey, Maurice B.
Coleman, Helen G.
Viratham-Pulsawatdi, Amelie
McCombe, Kris
Murray, Graeme I.
Blake, Andrew
Domingo, Enric
Robineau, James
Brown, Louise
Fisher, David
Seymour, Matthew T.
Quirke, Phil
Bankhead, Peter
McQuaid, Stephen
Lawler, Mark
McArt, Darragh G.
Maughan, Tim S.
James, Jacqueline A.
Salto-Tellez, Manuel http://orcid.org/0000-0001-8586-282X
-
Funding
Funding for this research was provided by:
Cancer Research UK (R2111CNR)
RCUK | Medical Research Council
- License Information
-
More Information
Article History
Received: 16 December 2019
Revised: 9 June 2020
Accepted: 23 June 2020
First Online: 20 July 2020
Ethics approval and consent to participate
: This study was conducted according to the guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided informed consent for sampling of their cancer tissues. Ethical approval for use of the samples in research was granted for the Epi700 CRC cohort through the Northern Ireland Biobank (NIB13/0069, NIB13/0087, NIB13/0088 and NIB15/0168) and for the Grampian CRC cohort and S:CORT CRC cohorts through NHS REC proportionate review (OREC 17/YH/0415, OREC 15/EE/0241).
: Patient data were generated using anonymised identifiers and held within the Northern Ireland Biobank, the Grampian Biorepository and the stratified medicine consortium in colorectal cancer (S:CORT) within Oxford University.
: The data are held within the Northern Ireland Biobank and the stratified medicine consortium in colorectal cancer (S:CORT), respectively, and are available on application.
: Dr H.G.C. is a member of the Editorial Board for the <i>British Journal of Cancer</i>. Dr. G.I.M. reports grants from Vertebrate Antibodies and is a member of the Editorial Board for the <i>British Journal of Cancer</i>. Dr. P.Q. has research funding with Roche, GeneFirst and Amgen, previous research funding from Halio, consultancy with Nordlai-Adlyte and advisory boards with Merck, Amgen and Roche. Dr. M.S.T. is a senior scientific advisor to Philips Computational Pathology and Visiopharm and has received honoraria from Roche, AstraZeneca, Merck and GSK. These declarations of interest have no relationship with the submitted publication. The remaining authors declare no competing interests.
: The funders had no role in study design, collection, data analysis or interpretation of the data. This study was supported by a Cancer Research UK Accelerator grant and carried out in collaboration with the stratified medicine consortium in colorectal cancer (S:CORT), which is jointly funded by the Medical Research Council and Cancer Research UK.
